We recently reported that in multiple myeloma increased Th22 cell frequencies correlate with poor prognosis. Here we show that within the same patients' cohort Th17 cells associate with bone disease and not with prognosis. Thus, we propose that Th22 and Th17 cells play non-redundant roles in multiple myeloma and constitute independent therapeutic targets.
Keywords: BM mesenchymal stromal cells; BM microenvironment; IL-13; IL-17; IL-22; Th17 cells; Th22 cells; bone disease; disease prognosis; multiple myeloma.